|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.78 USD | +0.14% |
|
-1.16% | +29.67% |
| Dec. 15 | Gilead HIV combo of bictegravir & lenacapavir hits phase 3 goal | RE |
| Dec. 15 | Wolfe Research Adjusts Gilead Sciences PT to $150 From $140, Maintains Outperform Rating | MT |
Chart calendar Gilead Sciences, Inc.
Upcoming events on Gilead Sciences, Inc.
| 2026-02-09 | Q4 2025 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
| 2026-04-22 | Q1 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
| 2026-07-29 | Q2 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
| 2026-10-28 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
Past events on Gilead Sciences, Inc.
| 2025-12-14 | Ex-dividend day |
| 2025-12-08 | American Society of Hematology Meeting - Abstract #6284 |
| 2025-12-08 | American Society of Hematology Meeting - Abstract #6344 |
| 2025-12-08 | American Society of Hematology Meeting - Abstract #5882 |
| 2025-12-08 | American Society of Hematology Meeting - Abstract #5356 |
| 2025-12-08 | American Society of Hematology Meeting - Abstract #6194 |
| 2025-12-08 | American Society of Hematology Meeting - Abstract #805 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #3717 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #4411 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #3606 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #4503 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #4510 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #3714 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #671 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #569 |
| 2025-12-07 | American Society of Hematology Meeting - Abstract #203 |
| 2025-12-06 | American Society of Hematology Meeting - Abstract #1799 |
| 2025-12-06 | American Society of Hematology Meeting - Abstract #1588 |
| 2025-12-06 | American Society of Hematology Meeting - Abstract #1894 |
| 2025-12-06 | American Society of Hematology Meeting - Abstract #1799 |
Past dividends on Gilead Sciences, Inc.
| 2025-12-14 | Quarterly 0.79 USD |
| 2025-09-14 | Quarterly 0.79 USD |
| 2025-06-12 | Quarterly 0.79 USD |
| 2025-03-13 | Quarterly 0.79 USD |
| 2024-12-12 | Quarterly 0.77 USD |
| 2024-09-12 | Quarterly 0.77 USD |
| 2024-06-13 | Quarterly 0.77 USD |
| 2024-03-13 | Quarterly 0.77 USD |
| 2023-12-13 | Quarterly 0.75 USD |
| 2023-09-13 | Quarterly 0.75 USD |
| 2023-06-13 | Quarterly 0.75 USD |
| 2023-03-13 | Quarterly 0.75 USD |
| 2022-12-13 | Quarterly 0.73 USD |
| 2022-09-13 | Quarterly 0.73 USD |
| 2022-06-13 | Quarterly 0.73 USD |
| 2022-03-13 | Quarterly 0.73 USD |
| 2021-12-13 | Quarterly 0.71 USD |
| 2021-09-13 | Quarterly 0.71 USD |
| 2021-06-13 | Quarterly 0.71 USD |
| 2021-03-11 | Quarterly 0.71 USD |
Annual results
| Fiscal Period | December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 27 281 26 518 2.88% | 27 116 27 083 0.12% | 28 754 28 310 1.57% | 29 210 | 30 132 | 31 560 |
|
EBITDA Million USD | Released Forecast Spread | 14 283 13 783 3.63% | 13 177 13 123 0.41% | 11 287 10 600 6.49% | 15 978 | 16 554 | 17 244 |
|
EBIT Million USD | Released Forecast Spread | 12 180 12 141 0.32% | 10 484 10 687 -1.9% | 8 520 8 238 3.42% | 13 321 | 14 146 | 14 999 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 5 814 5 658 2.76% | 6 859 7 323 -6.33% | 690 498 38.57% | 10 022 | 10 871 | 11 502 |
|
Net income Million USD | Released Forecast Spread | 4 592 4 383 4.77% | 5 665 5 872 -3.52% | 480 282 70.44% | 8 283 | 8 946 | 9 628 |
|
EPS USD | Released Forecast Spread | 3,64 3,48 4.75% | 4,50 4,69 -3.96% | 0,38 0,10 274.46% | 6,86 | 7,49 | 8,07 |
| Announcement Date | 02/02/23 | 06/02/24 | 11/02/25 | - |
Quarterly results
| Fiscal Period | September | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 6 686 6 349 5.31% | 6 954 6 735 3.25% | 7 545 6 999 7.8% | 7 569 7 154 5.8% | 6 667 6 823 -2.29% | 7 082 6 964 1.69% | 7 769 7 459 4.16% | 7 673 | 7 039 | 7 492 | 7 743 | 8 143 |
|
EBITDA Million USD | Released Forecast Spread | -427 -889 51.98% | 3 959 3 365 17.67% | 3 948 3 498 12.86% | 3 807 3 255 16.94% | 3 589 3 423 4.85% | 3 981 4 110 -3.13% | 4 607 4 587 0.44% | 4 390 | 3 931 | 4 203 | 4 375 | 4 500 |
|
EBIT Million USD | Released Forecast Spread | -1 117 -1 679 33.48% | 3 265 2 739 19.18% | 3 258 2 721 19.75% | 3 114 2 876 8.27% | 2 893 2 825 2.4% | 3 290 3 235 1.71% | 3 921 3 482 12.6% | 3 159 | 3 197 | 3 491 | 3 723 | 3 824 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -4 486 | 2 053 1 733 18.45% | 956 1 652 -42.12% | 2 168 2 043 6.14% | 1 649 2 068 -20.24% | 2 429 2 355 3.14% | 3 641 2 628 38.56% | 2 338 | 2 603 | 3 187 | 2 827 | 2 950 |
|
Net income Million USD | Released Forecast Spread | -4 170 -2 888 -44.38% | 1 614 1 379 17.02% | 1 253 1 335 -6.15% | 1 783 1 605 11.1% | 1 315 1 546 -14.92% | 1 960 1 898 3.24% | 3 052 2 098 45.48% | 1 915 | 2 078 | 2 435 | 2 394 | 2 410 |
|
EPS USD | Released Forecast Spread | -3,34 -1,92 -74.06% | 1,29 1,13 14.13% | 1,00 1,08 -7.48% | 1,42 1,19 19.08% | 1,04 1,26 -17.23% | 1,56 1,48 5.12% | 2,43 1,69 43.48% | 1,60 | 1,62 | 1,87 | 1,97 | 1,95 |
| Announcement Date | 25/04/24 | 08/08/24 | 06/11/24 | 11/02/25 | 24/04/25 | 07/08/25 | 30/10/25 | - | - | - | - | - |
| 2026-01-05 | Q3 2025 Earnings Release | Add to your calendar Google Apple ICS format | |
| 2026-01-11 | Q2 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-15 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-20 | Q4 2025 Earnings Release | Add to your calendar Google Apple ICS format | |
| 2026-01-20 | Q4 2025 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-21 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-21 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-21 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-22 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format | |
| 2026-01-26 | Q3 2026 Earnings Release (Projected) | Add to your calendar Google Apple ICS format |
Past sector events for Gilead Sciences, Inc.
| 2025-12-10 | November 2025 Sales and Revenue Release | |
| 2025-12-10 | November 2025 Sales and Revenue Release | |
| 2025-12-09 | Q2 2026 Earnings Release | |
| 2025-12-09 | November 2025 Sales and Revenue Release | |
| 2025-12-09 | November 2025 Sales and Revenue Release | |
| 2025-12-05 | November 2025 Sales and Revenue Release | |
| 2025-11-30 | Q3 2025 Earnings Release | |
| 2025-11-27 | Q2 2026 Earnings Release | |
| 2025-11-19 | Q3 2025 Earnings Release | |
| 2025-11-14 | Q2 2026 Earnings Release |
Quarterly revenue - Rate of surprise
Net sales - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- GILD Stock
- Calendar Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
















